Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Supportive care and prophylaxis of the side effects of myeloma drugs

Heinz Ludwig • 17 May 2019
COMy 2019
Multiple Myeloma Apixaban Carfilzomib

Heinz Ludwig, MD, PhD, of Wilhelminen Cancer Research Institute, Vienna, Austria, talks about the importance and advantages of supportive care for patients with multiple myeloma (MM). Dr Wilhelminen discusses the new advances for prophylaxis, particularly thromboprophylaxis. Secondly, he discusses the risks of cardiotoxicity caused by many MM drugs and how to supportively care for patients. Finally, Dr Wilhelminen discusses thrombotic microangiopathy, which he says is considered an emergency state. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Heinz Ludwig

2:50
Immunotherapy highlights at IMS 2023: bispecific antibodies, CAR-T cells & unanswered questions
Heinz Ludwig • 27 Sep 2023
2:02
Issues with CAR-T slot allocation in myeloma & the promise of locally manufactured products
Heinz Ludwig • 27 Sep 2023
3:49
Advances in technologies used to assess immune function in myeloma
Heinz Ludwig • 27 Sep 2023
2:59
Managing COVID-19 risks and exposures in patients with myeloma
Heinz Ludwig • 12 May 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals